(1)
Patent protects Company s lead clinical asset FS118 throughout Europe
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.
According to the EPO s decision, grant of European Patent number 3472207 will take effect on January 20, 2021. The decision to grant this patent follows the EPO s December 10, 2020 notice of intent to issue the patent, which was not challenged by any third party.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
F-star Therapeutics, Inc: F-star Therapeutics to Participate in Upcoming Conferences
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces that members of the management team will be participating in the H.C. Wainwright BioConnect Conference, the LifeSci Advisors 10th Annual Corporate Access Event and the B Riley Oncology Event. All events will take place virtually.
Details for the events are as follows:
H.C. Wainwright BioConnect Conference
Dates: January 11-14, 2021
1x1 Meetings with Management
7 steps to fast track your business recovery from the pandemic | Cloud itp.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itp.net Daily Mail and Mail on Sunday newspapers.